Currently, the increase in comorbid pathology, including patients with bronchoobstructive and cardiovascular diseases remains an urgent problem. Therefore, there is a need not only for new approaches in the tactics of management and treatment of patients with combined cardiorespiratory pathology, but also a more complete understanding of the impact of existing bronchodilator therapy on comorbid pathology and the pathophysiological changes taking place in order to create a new approach to the diagnosis and selection of effective and optimal treatment. The article provides a review of the literature on the impact of beta-2-agonists on pro- and anti-inflammatory mechanisms in patients with bronchial obstruction, including cardiovascular disease.

The management of patients with cardiovascular pathology and comorbid obstructive pulmonary diseases seems to be an urgent problem against the background of their widespread prevalence among the adult population. According to the latest recommendations of GOLD 2017, it is not possible to diagnose COPD and to select options for pharmacotherapy without assessing the symptoms. Evaluation of symptoms in patients with cardiorespiratory pathology is a key element in the diagnosis of both respiratory and cardiovascular deseases. It is important to conduct differential diagnosis of both nosologies for reliable evaluation of the results of standardized respiratory questionnaires. Many respiratory questionnaires have been developed now; some of them have been validated and recommended for use in clinical practice in patients with COPD and asthma. However, their sensitivity and specificity are different, these questionnaires can`t be used interchangeably. In some cases, a decrease in the informative value of standardized respiratory questionnaires was revealed in patients with comorbid cardiovascular and obstructive pulmonary diseases. There are extremely few scientific works, that assess the same aspects of this problem. In connection with this, the development of specialized questionnaires for patients with comorbid cardiovascular and obstructive pulmonary pathology is relevant.